Longer‐acting clotting factor concentrates for hemophilia

• Published in: Journal of thrombosis and haemostasis Vol. 13; no. S1; pp. S167 - S175
• Main Author: Powell, J. S.
• Format: Journal Article
• Language: English
• Published: England Elsevier Limited 01.06.2015
• Subjects: Animals; blood coagulation factors; Blood Coagulation Factors - adverse effects; Blood Coagulation Factors - pharmacokinetics; Blood Coagulation Factors - therapeutic use; Drug Discovery; Drugs, Investigational - adverse effects; Drugs, Investigational - pharmacokinetics; Drugs, Investigational - therapeutic use; factor IX; factor VIIa; factor VIII; Hemophilia; Hemophilia A - blood; Hemophilia A - diagnosis; Hemophilia A - drug therapy; Hemorrhage; Hemorrhage - prevention & control; Hemostasis - drug effects; Hemostatics - adverse effects; Hemostatics - pharmacokinetics; Hemostatics - therapeutic use; Humans; pharmacokinetics; prophylaxis; Recombinant Fusion Proteins - therapeutic use; Treatment Outcome; blood coagulation factors; pharmacokinetics; factor IX; factor VIIa; factor VIII; prophylaxis

Summary Hemophilia, when severe, leads to spontaneous life‐threatening bleeding episodes. Current therapy requires frequent intravenous infusions. Most patients must limit their physical activities to avoid bleeding when the factor activity levels are below normal. In 2014, new therapeutic factor VI...